Workshop 14
Antiviral therapy and resistance I

Programme

• 08:30 – 08:45 12 Min. 3 Min.

  • Abstract talk
  • O 077

  Granger-causality analysis reveals antiviral potential of defective viral genomes from time series data

  • Mia Le (Hamburg / DE)

   Antiviral therapy and resistance
• 08:45 – 09:00 12 Min. 3 Min.

  • Abstract talk
  • O 078

  Vesicular stomatitis virus (VSV) as mutational tool to predict antiviral resistance

  • Francesco Costacurta (Innsbruck / AT)

   Antiviral therapy and resistance
• 09:00 – 09:15 12 Min. 3 Min.

  • Abstract talk
  • O 079

  BKPyV in primary renal proximal tubular epithelial cells: life cycle analysis and characterisation of novel small molecule inhibitors

  • Clara Husser (Hamburg / DE)

   Antiviral therapy and resistance
• 09:15 – 09:30 12 Min. 3 Min.

  • Abstract talk
  • O 080

  Unraveling the Role of the BGLF4 Kinase in Epstein-Barr virus (EBV) Replication: Novel Host Targets and Inhibitors

  • Melanie Kögler (Erlangen / DE)

   Antiviral therapy and resistance
• 09:30 – 09:45 12 Min. 3 Min.

  • Abstract talk
  • O 081

  Orally Bioavailable RORγ/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity

  • Dr. Friedrich Hahn (Erlangen / DE)

   Antiviral therapy and resistance
• 09:45 – 10:00 12 Min. 3 Min.

  • Abstract talk
  • O 082

  Cyclosporin A triggers a RIG-I-mediated interferon response through accumulation of mitochondrial dsRNA by impairing autophagy

  • Lars Meier (Marburg / DE)

   Antiviral therapy and resistance